UK’s CMA Doubles Down On Liothyronine Objections
Following Ruling On Unfair Pricing For Phenytoin In March
The UK’s CMA has reiterated its belief that Advanz Pharma charged excessive and unfair prices for liothyronine in the UK, following a separate ruling that provided detailed guidance on how such matters should be evaluated.
You may also be interested in...
Three years after rebranding from Concordia, Advanz Pharma is to be swallowed up by European-focused private equity Nordic Capital.
A UK appeals court has provided detailed guidance on how the country’s Competition and Markets Authority should evaluate unfair pricing, as part of a ruling that upholds a previous decision to overturn CMA fines of almost £90m ($112m) imposed on Pfizer and marketing partner Flynn Pharma over pricing for phenytoin sodium capsules.
Advanz Pharma is considering slimming down its US operations as it searches for global product deals and company acquisitions in western Europe to restore sales growth.